Sanofi and Alnylam have concluded the research and option phase of the companies’ 2014 RNAi therapeutics alliance in rare genetic diseases. The collaboration terms for patisiran, vutrisiran (ALN-TTRsc02) and fitusiran, will continue unchanged.   As part of this agreement, Alnylam will advance an additional investigational asset in an undisclosed rare genetic disease through the end of IND-enabling studies and Sanofi will be responsible for any potential further development or commercialization...